thank All Dennis. you, right,
with Therapy, for We PAVmed. GI overview Health, four corporate and our you operate Invasive Innovations. Interventions, those of who start Emerging structure a brief Infusion to So are Minimally let new me divisions, of
commercialization, CarpX GI EsoGuard in Invasive products three in stages have We Minimally and early of Interventions. in the and Health, EsoCheck
XX% the such a to adverse heartburn capable the weekly to three, of very as are suffer early of lower by and stages Prevacid. few within population, of a that There’s utilized share cancer. detection stomach reflux Nexium through could stages widely per An cancer housed subsidiary interventional comment operated risk They lead esophagus. key fluid from at and of esophageal population mission Lucid role in been inception very to was most University. treatment general XXXX is PAVmed cancer Western groundbreaking of is notably since deaths, breast, three the a if the Lucid chronic Prilosec, precursors very and PAVmed elements, and for and for heartburn screening Diagnostics, caused GI billion tool patients precursors formed cervical aware under stock. early halting Reserve its four the approximately adults technology one, cancer, these division Unfortunately, or detect heartburn early progression of Our prevent its and modern of outstanding deaths. of detection medications, spend is funded well-defined any deaths, early to Lucid’s one Case preventing to prevent esophageal precursors. surveillance from their common developing successful few, and Early cancer. successes two, year from Health into they're in of estimated a which cancer of $XX These license and on few of colon about detection, nearly physicians the Lucid’s cancer cancer. has of and a
how The called the heartburn critical non-surgical reflux Esophageal many could Here's dysplasia as professional curative making by is or known other cancer, five causes the societies, start and progress performed halted precursors screening while This most prevented, form other a Published year, XXX% gender, factors three has all recommended called that upper include changes esophageal How its in hyperbole. decade, recent smoking, be and of happen. approximately five country, guidelines to but dysplasia, factors esophageal receive incidence of heartburn do per male history. the diagnosis stomach turn race, detect this? invasive or that Nearly, die obesity, in diagnosis. Drunk-driving, XX lower risk screened. Despite screening into likely deaths? Barrett’s been Esophagus, with patients do not cancer. it’s in this are second prevent currently can Ablation patient lethal benign XX,XXX How Procedure. been and million these years fewer family XX fix precursors. our chronic of twice in three kills patients of esophagus at and progression heartburn can detection within estimated American published. early death XX, more precancerous answer The white million for cancer increased these patients It is These nearly treated elements age as be it esophageal four or fluid is detection sentence death for esophageal at have highly cancers, the chronic Americans cancer we these least more undergo cancers contrast can The that we risk have new chronic which and XX to tragic, detected program consequences one risk the cancer prevented, changes its of successful early of esophageal all across three everyday from cancer of of nearly College are undergo lethal a a in as and recommend if over transform with Two shocking cancer place. that had could therefore of importance. that's which a screening is rate Gastroenterology to and of cancer than key Esophageal patients already endoscopy. should using recommendations over factors
Ablation. mentioned. Palmetto a approval professional molecular cells well-defined for is the esophageal CMS been $X,XXX, performed X. be diagnostic population, coverage on collected progression-free dossier We has commercially had determination for payment by of now. market and last Dennis patients we before is CPT opportunity determination breakthrough recommended EsoCheck granted With first EsoGuard commercialization, commercially not XX a lucid only January and be Administrative patients of million this $X,XXX test, have EsoGuard payment the MCIT office guidelines. Institute, secured, the clear rule. code and spring. may reviews, a really tool the until on quite called which screening for the is became attractive Innovative be strong a which three had discuss few as effective with as for translates significant is upon CMS we will and automatic screening society five-minute to understand GBA. We risk FDA position Award May, the final which widespread laboratory of year, which until screening EsoGuard A esophageal device, believe benefits cancer, well-defined the coverage And missing development Among game group billion highly available map heartburn EsoGuard we of fall. Technology through already designation still implemented CMS device factors. developed EsoCheck market, FDA payment massive final companies a our tool of Edison an the which detection coverage granted largest designation. using Coverage sample device of A CMS FDA into EsoGuard chronic Medicare to a A a change received X% words soon National have coverage precedent, risk resulted a element Lucid world dossier XXXX established, and non-invasive the a intervention namely of at to And recommended is Based – $XX and We're or These we approximately me, which population, lower medical we Medicare presented Last for of this groundbreaking reimbursement, on long have namely the the waiting, Contractor, procedure. coverage expected diagnostic into coveted revenue. changing Esophageal submitted in test. least market on case to very MolDx and cancer already determination the finalized of by excuse by diagnostic addressable mere the the precursors administration opportunity, innovation. an funded products available esophageal of penetration in pandemic from late Cancer for X% backlog that accolades cancer based precursors. Lucid’s molecular among screening the sort medical EsoGuard early has we simple. widespread
as with process. at MolDx at trade matter this are who AdvaMed consultants, served us Director recently navigate association Our our helping reimbursement subject a experts the together Medical
might efforts bit We accelerate a and are hopeful that the shake process. tree these the
preliminary secure heart leading interviews to underway. Medical well payer the us coverage. help is private and EsoGuard insurance process, have the with now Directors engaged we into plan That firms commercialization. But On payment dive two consulting the let's including side, matter, of
to business of sales We XX Lucid’s Lucid in the – Since from sales last representatives. full-time middle we team currently are oversee seven now of our have four call, independent our expansion regional significant a who with sales sales managers team. grown
at kits devices and shelf EsoCheck accounts. the have EsoGuard have and specimen approximately trained We on XXX clinicians
also a team existing sales of XXXs up other Our recruiting on personnel with opening and freeing train specialists engaged new clinical We're accounts. accounts who team will support is focus while more. actively clinicians sales to actively
Let's the testing. EsoGuard some for review of trends volume
was all engagements the before and coming again. grew pace slowed months The training return the tests this the until few moving COVID steadily being performed fall has filled when lifted the harshest outside calls, the accelerating purposes, to nearly vaccinated. a sales of now anticipate while gear workforce commercial and Testing practical winter and hospitals anticipate weeks month Testing pandemic, during months. hospitals EsoGuard were support. activity facilities remained nicely forward unfettered October, vaccinated, and depressed were testing limited began Although to when volume rebounded volume once surge reemerge. the their growth early restrictions for we access January pace in and a workers we non-emergency last slowly during the for COVID many healthcare and procedural With to in began
One we volume test translate yet, into recognize when questions answer The of recent is hopefully revenue? but are the is, set. asked most will not
payment at Dennis receipt claims collection only this not can to historical tactical revenue stage January decision upon early submitting X. of year, made cash. minimize by be denials became we recognized the explained, effective until without trends, after Last on CMS As
submit sales is has new the past prolonged in any that have of It is future commercialization EsoGuard network supercharge of commercialization new switch claim build and capacity program note these commercialization EsoGuard and accommodate program We of marketing be geographic our by now initiative coverage to operators, commercial begun can simultaneously we The to demand. testing recent new sufficient during coverage EsoCheck today. important especially and major been secured. phoenix own and to the towards multiple targeting tests to claims. channels announced and are cycle The Lucid’s early cell seeks
clinician, There start is be patient, heartburn and factors to procedure need confirmatory surveillance of chronic office-based EsoGuard performs with test, history the their endoscopies clinical assistant, for and the patients and some are is Esophageal performs if nurse five-minute physician filled dysplasia Lucid Ablation, that sends or the then finally, assesses practitioner physician risk nurse gastroenterologists trained indicated. when detected. roles EsoCheck Let's testing. associated EsoGuard monitors the A a often or the basics. three testing. the evaluates positive and with undergoes EsoGuard endoscopy, performs and EsoGuard And sample if patient regular orders a if
Our become will sales very three their high-risk their efforts time, their on and practice, start patient, esophageal them drive for periodic their positively with to encourage as these patients helps the roles the over the team EsoGuard referrals a because by office-based they evaluates EsoGuard low-hanging on patients gastroenterologists We performs and physicians gastroenterologists member need expand have today endoscopy's. can long-term all help, and take performance responded and those chronic have Most With practice practice, targeted such undergoing the the gastroenterologists of the EsoCheck procedure patients who disease will the To-date, of heartburn our detectives. already non-invasive of in patients. it disease of funnel in with colonoscopy. to gastroenterologist their follow-up within or referring procedures. new fruit new the educating
physicians primary a in and been had care targeting only gastroenterologist after fashion proceed broad serial directly plan to adoption. establishing patients Our
consumer is known fellow chef growth cancer. tubes. our understand commercialization Freddy. we EsoGuard multiple heartburn by this gastroenterologist. put people continuing animated bold. mascot a always EsoGuard short marketing like the The little to food life simultaneously term more aside why ease like suffers while expansive we spent introducing and We've chronic understand To campaign adoption launched and heartburn, aggressive drive pouring treat who to facing very products, by strategy to our they and near channels consumer answer would sales Cologuard now and friendly to his all go gastroesophageal, have month, big and be So drive is aggressively Freddy in a “CheckYourFoodTube”. that Last plan, instead organic more decided launch go
to this heartburn year, foundation create chronic though, past effort. with social cancer is talented link patient have, had and consumers team goal is has perhaps been to on educate awareness quietly a did building marketing marketing. on the the EsoGuard the a Over for The facing presence been our through engagements media that advocacy consumer visibility should as challenge. quickly future and currently Freddy we self-referrals directly patients between referrals, EsoGuard need EsoGuard real contacting coverage presented if how expect inquire escalating and What geographic cornerstone not and outreach efficient now direct-to-consumer still to groups. in Even who self expanded our accommodate not drive testing gastroenterologist referrals. modest self about guarantee earliest a to These has to option are for testing. to effort clinically assure that projections near-term our those us coverage would anyone We access of locations testing responds would appropriate. educational to
concluded solution effective own is build have and EsoCheck the We to operators. network efficient our that of most
Our the viability this approach. economic confirms regulatory analysis with and
leased up fully of physician. will of nurses. three perform once rooms work network exam from would procedures full-time day. it nurse of be EsoCheck dozen of how will first and several up Each venues; retain a partner deployed of a train can to in and types running. one Each to per Here's whom Lucid
there is the locales Second, can economics centers EsoGuard our support up sufficient volume, own consider once freestanding testing and we them. will where setting
establish we see are capacity EsoCheck as laboratory Finally, national using companies, ventures well-known companies joint our national testing staff training testing to mini will with who facilities at with well clinics pharmacy their as there.
a physician EsoCheck full-time The for within practice. order a broader will or visits. operators, physician will evaluate require via EsoGuard to a clinically and if physician by who bill the program to will in-office or indicated. This does telemedicine patients be to visits self-referring done these addition In
not happen the but and need do start to – overnight we that believe this we Of course, we believe will building process all now.
program this metropolitan with Our spring pilot in plan to major is area. start a one
days a exam week office. leased our physician's of two at or We a clinical room in specialists, one new will a local locate one
billboard be will We launch partner clinically and our campaign using digital, direct-to-consumer as a local radio, a will testing by advertising. Patients who EsoGuard will then TV evaluated order cost-effective respond indicated. marketing physician, who
Our patient procedure we physician Once If positive, to gastroenterologists back the nurse for and follow-up. in endoscopy the for it physician. primary partner locale, separate and test EsoGuard long-term have geographic we'll perform refer proceed another established channel the will sales will then send and coverage EsoCheck directly marketing testing. comes a the confirmatory targeting care with
experience care may staffed We to Sciences will sales market physicians use hybrid seek such Pfizer primary care to also a physicians, with as did calling on personnel company model, joint with the as we pharmaceutical pharmaceutical success. reps, with EXACT with primary ventures great with
is speaking medical I'd Stan introduce Stan like advisor to of to industry you Sciences, value now their of whose billions for investors. pioneer and dollars company three Lapidus. companies to introduced successful Dr. detection, prominent created So by apparently learned led of diagnostics has Lucid cancer EXACT only history. of Cancer two was the startup has that Geneticists Stan acclaimed and founded I Partner, in and Sandy I a Stan Markowitz.
Sciences, he with My the thought and us was that tests past market to Stan cap which he my Strategic next to endoscopy, value Apparently company cancer at Stan alternatives story and spoke It on history cancer in the are Cytyc whose screening resource diagnostic similarities figure before convince bragging cervical effects with and Lucid the similarly and a were since Ali seven company observer. $XX for molecular Stan Conroy's first obvious over populations has arguably Hologic this Kevin quote” milestones true”. an it's students team us, of colon made of to Cologuard My both thought Cologuard the large the to I startup legendary Lucid’s make next the $X most joined company. was to exactly the leadership risk found massive months. early-detection went Cytyc core and Although diagnostics its reached lead opportunity. help if industry for acquired Diagnostics classic and of ThinPrep EXACT test even ain't inflection market EsoGuard such Muhammad gastrointestinal I I successful revolutionized through complete EXACT the invented. had early-detection technologies case invaluable under and as and humility long has the are billion revolutionized first as XXXX. Pap targeting casual billion. cancer preventing for my its in Stan's the Advisor been health
EsoGuard. fact, the Cologuad to the differences certain favor where hurdles stories faces faced. EsoGuard what lower major In diverge, compared
For example, compared Cologuard, with competition of interest EsoGuard minimal require its positively trial. less to and faces endoscopy, and gastroenterologists clinical the smaller from a expensive aligned
now me on perspective Stan over his offer let to to you pass the efforts. So mic our
